Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
General Objectives:
- To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
- To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Cancer Liver Metastases |
Drug: Cetuximab Procedure: Liver resection Drug: Cetuximab and FOLFIRI Drug: Cetuximab and FOLFOX |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases |
- Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population
- Rate of R0 liver resection (ITT- population)
- Progression free survival (ITT- population)
- Disease free survival after resection (ITT- population)
- Overall survival (ITT- population)
- Safety (all patients that received any study drug)
- Molecular predictive markers for response and toxicity
| Enrollment: | 135 |
| Study Start Date: | November 2004 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Cetuximab and FOLFIRI
|
Drug: Cetuximab
Procedure: Liver resection
Drug: Cetuximab and FOLFIRI
Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by: Cetuximab 250 mg/m² (1.0 h i.v.) weekly Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.) Other Names:
|
|
Active Comparator: 2
Cetuximab and FOLFOX
|
Drug: Cetuximab
Procedure: Liver resection
Drug: Cetuximab and FOLFOX
Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by: Cetuximab 250 mg/m² (1.0 h i.v.) weekly Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.) Other Names:
|
Detailed Description:
Patients with liver metastasis will be screened for this study. Eligible patients will complete the pretreatment evaluation including an abdominal CT scan that will be presented to the local surgeon and the radiologist for proving of resectability of hepatic lesions. Additionally, CT scans will be reviewed by three reference surgeons. In case of non-resectability, as defined above, CT- or ultrasound- guided biopsy of one of the liver metastases will be performed, unless biopsy material is available from prior biopsy of one of the liver metastases.
Instead of an ultrasound-guided biopsy, a CT-guided biopsy may be performed.
Formalin-fixed, paraffin embedded metastatic tissue will be sent to reference laboratory (Prof. Störkel, Wuppertal) for immunohistochemical analysis of EGFR- expression.
Additionally tissue will be stored in "RNA later" for gene expression analysis if agreed by the patient.
Additionally, the primary tumor will be collected and sent to the reference laboratory for analysis of EGFR- expression (if agreement of the patient exists).
Patients will be randomized to a combination of:
Cetuximab/FOLFIRI (irinotecan/5-FU/FA) or Cetuximab/FOLFOX6 (oxaliplatin/5-FU/FA)
All patients receive a four month treatment (eight cycles) of the allocated treatment.
Resection is planned after completion of neoadjuvant treatment and should be performed between 4 and 6 weeks after the last dose of chemotherapy. Probes of the resected material (in liquid nitrogen and paraffin embedded material will be collected).
If a resection is not possible after eight administrations of chemotherapy, chemotherapy will be continued until tumor progression (maximal duration of treatment 2 years) and the patient will be evaluated for a potential resection every two months.
After resection, postoperative treatment is planned for 3 months (6 cycles). Treatment start is planned between 4 and 8 weeks after the operation.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).
- Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.
- Karnofsky Performance Status ≥ 80
- Informed consent
- Adequate bone marrow function, liver and renal function (neutrophils > 1.5 x 10^9/l; thrombocytes > 100 x 10^9/l; hemoglobin > 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT < 5 x UNL; serum creatinine ≤ 1.5 x UNL)
- Age ≥ 18 years
Exclusion Criteria:
- Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence
- Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)
- Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy
- Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry
- Concurrent systemic immune therapy, chemotherapy, or hormone therapy
- Investigational agents or participation in clinical trials within 30 days before start of the treatment in study
- Clinically relevant coronary disease or myocardial infarction within 12 months before study entry
- Peripheral neuropathy > CTC grade I
- Inflammatory bowel disease
- Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
- History of severe psychiatric illness
- Drug or alcohol abuse
- Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)
Contacts and Locations| Austria | |
| Medizinische Universitaet Wien, Universitaetsklinik für Chirurgie | |
| Wien, Austria, A-1090 | |
| Germany | |
| Kreiskrankenhaus Aschersleben | |
| Aschersleben, Germany, 06449 | |
| Charite-Campus Benjamin Franklin, Innere Medizin | |
| Berlin, Germany, 12200 | |
| Charite-Campus, Virchow-Klinikum, Innere Medizin | |
| Berlin, Germany, 13353 | |
| Allgemeines Krankenhaus Celle | |
| Celle, Germany, 29223 | |
| University Hospital "Carl Gustav Carus" | |
| Dresden, Germany, 01307 | |
| Florence-Nightingale-Krankenhaus | |
| Duesseldorf, Germany, 40489 | |
| Universitaet Erlangen-Nuernberg, Chirurgie | |
| Erlangen, Germany, 91054 | |
| Westdeutsches Tumorzentrum, Universitaetsklinikum Essen | |
| Essen, Germany, 45112 | |
| Johann Wolfgang Goethe Universitaet, Chirurgie | |
| Frankfurt Main, Germany, 60596 | |
| Westpfalz-Klinikum GmbH Innere Medizin I | |
| Kaiserslautern, Germany, 67653 | |
| UKSH Campus Kiel, II. Medizinische Klinik | |
| Kiel, Germany, 24116 | |
| Staedtisches Klinikum Magdeburg-Olvenstedt | |
| Magdeburg, Germany, 39130 | |
| Universitaetsklinik Mannheim gGmbH, III. Medizinische Klinik | |
| Mannheim, Germany, 68167 | |
| Klinikum Grosshadern, III. Medizinische Klinik | |
| Muenchen, Germany, 81377 | |
| Klinikum Oldenburg GmbH | |
| Oldenburg, Germany, 26133 | |
| Klinikum Passau, II. Medizinische Klinik | |
| Passau, Germany, 94032 | |
| Klinikum der Hansestadt Stralsund GmbH, Medizinische Klinik | |
| Stralsund, Germany, 18435 | |
| Krankenhaus der Barmherzigen Brueder Trier, Chirurgie | |
| Trier, Germany, 54292 | |
| Universitaetsklinikum Tuebingen | |
| Tuebingen, Germany, 72076 | |
| Universitaetsklinikum Wuerzburg, Chirurgie | |
| Wuerzburg, Germany, 97080 | |
| Principal Investigator: | Claus-Henning Köhne, Prof. Dr. | Klinikum Oldenburg GmbH, Dr.-Eden-Str.10; 26133 Oldenburg |
| Principal Investigator: | Gunnar Folprecht, Dr. | University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany |
More Information
No publications provided by Dresden University of Technology
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Prof. Dr. Claus-Henning Köhne, now: Klinikum Oldenburg gGmbH |
| ClinicalTrials.gov Identifier: | NCT00153998 History of Changes |
| Other Study ID Numbers: | CELIM |
| Study First Received: | September 8, 2005 |
| Last Updated: | February 26, 2009 |
| Health Authority: | Germany: Paul-Ehrlich-Institut |
Keywords provided by Dresden University of Technology:
|
Cetuximab Oxaliplatin Irinotecan 5-FU |
Chemotherapy Resection Liver resection Neoadjuvant |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Neoplasm Metastasis Neoplasms, Second Primary Liver Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplastic Processes |
Pathologic Processes Liver Diseases Fluorouracil Oxaliplatin Irinotecan Cetuximab Leucovorin Folic Acid Levoleucovorin Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antimetabolites, Antineoplastic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013